This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human FABP2 / I-FABP Protein, His Tag
catalog :
FA2-H5149
quantity :
200 ug, 1 mg
price :
270 USD, 980 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
FA2-H5149
product name :
Human FABP2 / I-FABP Protein, His Tag
quantity :
200 ug, 1 mg
price :
270 USD, 980 USD
quantity & price :
$270/200ug,$980/1mg
target :
FABP2
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human FABP2, His Tag (FA2-H5149) is expressed from E.coli cells. It contains AA Ala 2 - Asp 132 (Accession # P12104-1).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>98% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human FABP2, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 98%.
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Fatty acid-binding protein 2 (FABP2), is also known as Fatty acid-binding protein, intestinal (FABPI), Intestinal-type fatty acid-binding protein (I-FABP). FABP2 belongs to the calycin superfamily and Fatty-acid binding protein (FABP) family. FABP2 / FABPI is expressed in the small intestine and at much lower levels in the large intestine and is highest expressed in the jejunum. FABP are thought to play a role in the intracellular transport of long-chain fatty acids and their acyl-CoA esters. FABP2 is probably involved in triglyceride-rich lipoprotein synthesis. FABP2 binds saturated long-chain fatty acids with a high affinity, but binds with a lower affinity to unsaturated long-chain fatty acids. FABP2 may also help maintain energy homeostasis by functioning as a lipid sensor.
References :
(1) Pelsers M.M.A.L., et al., 2003, Clin. Biochem. 36:529-535.
(2) Darimont C., et al., 1999, Am. J. Physiol. 276:G606-G612.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments